David Loesch

Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study

Javier Cortés, Joyce O’Shaughnessy, David Loesch et al. · The Lancet · 2011 · 1.1K citations

Medicine, Oncology, Pharmacotherapy +9

Pilot Study Using Molecular Profiling of Patients' Tumors to Find Potential Targets and Select Treatments for Their Refractory Cancers

Daniel D. Von Hoff, Joseph J. Stephenson, Peter J. Rosen et al. · Journal of Clinical Oncology · 2010 · 643 citations

Medicine, Molecular Medicine, Oncology +17

Randomized Phase III Study of Trastuzumab, Paclitaxel, and Carboplatin Compared With Trastuzumab and Paclitaxel in Women With HER-2–Overexpressing Metastatic Breast Cancer

Nicholas J. Robert, Brian Leyland‐Jones, Lina Asmar et al. · Journal of Clinical Oncology · 2006 · 484 citations

Medicine, Oncology, Pharmacology +17

Phase III Study of Immediate Compared With Delayed Docetaxel After Front-Line Therapy With Gemcitabine Plus Carboplatin in Advanced Non–Small-Cell Lung Cancer

Panos Fidias, Shaker R. Dakhil, Alan P. Lyss et al. · Journal of Clinical Oncology · 2008 · 422 citations · Full text

Medicine, Oncology, Pharmacology +15

An Outbreak of Infections Caused by Strains of Staphylococcus aureus Resistant to Methicillin and Aminoglycosides.

Kent Crossley, David Loesch, Barbara Landesman et al. · 1979 · 185 citations

Life Sciences, Infectious Diseases, Microbiology +12